Kailazarid Gomez

TL;DR: None of the drug regimens evaluated reduced the rates of HIV-1 acquisition in an intention-to-treat analysis, and adherence to study drugs was low.

TL;DR: Even allowing for 100-fold concentration differences due to poor adherence or less frequent prescribed dosing, vaginal dosing of tenofovir should provide higher active site concentrations and theoretically greater PrEP efficacy than oral dosing; randomized topical dosing PrEP trials to the contrary indicates that factors beyond ten ofovir’s antiviral effect substantially influencePrEP efficacy.

TL;DR: VivaGEL was generally well tolerated and comparable with the VivaGel placebo, although there was a higher incidence of low-grade related genital adverse events compared to the HEC placebo gel.

TL;DR: A role for oral and vaginal PrEP formulations is indicated and the importance of integrating pharmacokinetics-based adherence assessment in future trials is highlighted, noting the need to consider geographic and cultural experience with product formulations, partner involvement, and sexual health benefits that ultimately influence use.

TL;DR: NET-EN might be an alternative injectable drug with a lower HIV risk than DMPA in high HIV-1 incidence settings where NET-EN is available, and moderate associations in observational analyses should be interpreted with caution.